Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 15/20 | 0.68 |
| ▸ | HRH1 | P35367 | 15/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.55 |
| ▸ | PLD2 | O14939 | 1/20 | 0.54 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401180 | 0.92 | CCR3 (0.69) | CCR3HRH1KCNH2CCR1 | |
| SCHEMBL6404481 | 0.91 | CCR3 (0.65) | CCR3HRH1KCNH2CCR1 | |
| SCHEMBL6398901 | 0.91 | CCR3 (0.68) | CCR3HRH1KCNH2CCR1 | |
| Hydrochloric Acid SCHEMBL5657083 | 0.90 | CCR3 (0.64) | CCR3HRH1KCNH2CCR1 | |
| SCHEMBL6394746 | 0.89 | CCR3 (0.71) | CCR3HRH1KCNH2CCR1 | |
| SCHEMBL6397874 | 0.89 | CCR3 (0.65) | CCR3HRH1KCNH2PLD2PLD1 | |
| SCHEMBL6395052 | 0.88 | CCR3 (0.79) | CCR3HRH1KCNH2 | |
| SCHEMBL6397121 | 0.88 | CCR3 (0.61) | CCR3HRH1KCNH2CCR1 | |
| SCHEMBL6401293 | 0.87 | CCR3 (0.66) | CCR3HRH1KCNH2CCR1 | |
| SCHEMBL5375878 | 0.86 | CCR3 (0.59) | CCR3HRH1KCNH2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | claimed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | claimed |
| JP-2002540204-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1165545-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058305-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-05 | — | — | WO | claimed |
| US-6946478-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | disclosed |
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | disclosed |
| EP-1165545-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058305-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134840-A1 | Novel compounds | RPS4X, RPS4Y1, CYP4B1 | CCR3 894/4885HRH1 802/4885KCNH2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.